Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (NASDAQ: CCCC) is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for cancer and other challenging diseases. This news hub provides investors and industry professionals with timely updates on the company's scientific advancements, regulatory milestones, and strategic initiatives.
Access official press releases, clinical trial progress reports, and partnership announcements in one centralized location. Our curated collection includes updates on key pipeline assets like cemsidomide and CFT1946, collaboration developments with Biogen and Merck, and financial disclosures essential for informed decision-making.
Discover comprehensive coverage of C4 Therapeutics' innovative TORPEDO® platform advancements, protein degrader research breakthroughs, and participation in major medical conferences. All content is sourced directly from company filings and verified industry publications to ensure accuracy.
Bookmark this page to stay informed about CCCC's progress in developing novel therapies that address drug resistance and undruggable targets through targeted protein degradation science. Check regularly for new developments in this cutting-edge area of biopharmaceutical research.
C4 Therapeutics has appointed Ron Cooper as the new Chairman of the Board.
He brings extensive global pharmaceutical and biotechnology experience.
Bruce Downey will remain on the Board and chair the Organization, Leadership, and Compensation Committee.
Glenn Dubin is stepping down from the Board.
C4 Therapeutics aims to become a fully integrated biotechnology company, focusing on targeted protein degradation science.
Ron Cooper's past roles include leadership positions at Albireo Pharma and Bristol-Myers Squibb.
His experience spans across discovery, development, and commercialization of pharmaceutical products.
CEO Andrew Hirsch expressed excitement about Cooper's appointment and the future growth of C4 Therapeutics.
C4 Therapeutics, a biopharmaceutical company, reported strong financial results for the first quarter of 2024. They earned an $8 million payment from Biogen, established a research collaboration with Merck KGaA, and advanced Phase 1 trials for CFT7455 and CFT1946. The company's cash position stood at $299.2 million, providing runway into 2027.
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
